Which HEDIS measure pertains to anticoagulation therapy for patients with atrial fibrillation?

The Anticoagulation Therapy for Atrial Fibrillation/Flutter measure specifically addresses the management of patients with atrial fibrillation (AF) and ensures that they are receiving appropriate anticoagulation therapy. This is crucial as patients with AF are at a higher risk for stroke due to increased blood clots forming in the heart. The measure focuses on the percentage of patients with AF who are prescribed anticoagulants such as warfarin or direct oral anticoagulants to reduce the risk of stroke.

By adhering to this measure, healthcare providers can improve patient safety and outcomes by managing the risks associated with atrial fibrillation effectively. This focus on anticoagulation therapy reflects a commitment to evidence-based practices, as studies have shown that appropriate anticoagulation significantly lowers the incidence of strokes in these patients.

In contrast, the other measures listed do not directly address the specific needs of atrial fibrillation patients or the importance of anticoagulation therapy in their treatment plan.